Zhengye Biotechnology Stock (NASDAQ:ZYBT)


RevenueOwnershipFinancialsChart

Previous Close

$0.68

52W Range

$0.62 - $13.08

50D Avg

$0.86

200D Avg

$1.62

Market Cap

$30.62M

Avg Vol (3M)

$89.10K

Beta

-2.17

Div Yield

-

ZYBT Company Profile


Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CN

Employees

278

IPO Date

Jan 07, 2025

Website

ZYBT Performance


ZYBT Financial Summary


Dec 23Dec 22Dec 21
Revenue$211.65M$260.27M$214.07M
Operating Income$44.99M$65.83M$52.38M
Net Income$31.46M$46.73M$38.96M
EBITDA$72.10M$85.55M$70.12M
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in CNY

Peer Comparison


TickerCompany
EXOZeXoZymes, Inc.
PDEXPro-Dex, Inc.
CRDLCardiol Therapeutics Inc.
SRZNSurrozen, Inc.
APYXApyx Medical Corporation
ONCYOncolytics Biotech Inc.
TILInstil Bio, Inc.
SERASera Prognostics, Inc.
IXHLIncannex Healthcare Limited
ATOSAtossa Therapeutics, Inc.